Comparative Pharmacology
Head-to-head clinical analysis: CLOXAPEN versus PROBAMPACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOXAPEN versus PROBAMPACIN.
CLOXAPEN vs PROBAMPACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cloxapen inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBPs involved in the transpeptidation step of peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
PROBAMPACIN is a synthetic aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and preventing translocation of peptidyl-tRNA from the A-site to the P-site.
Oral: 250-500 mg every 6 hours. IV: 1-2 g every 4-6 hours.
100 mg IV every 12 hours over 30 minutes.
None Documented
None Documented
Terminal elimination half-life 1.5-2 hours; prolonged to 2.5-4 hours in severe renal impairment; clinical context: requires frequent dosing in normal renal function
4.5 hours (prolonged to 12-18 hours in severe renal impairment)
Renal 70-80% as unchanged drug and active metabolite; biliary 5-10%; fecal <5%
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic